Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update Clinical Trial Authorisation application for a ...
Clinical Trial Authorisation application for a Phase 1a/b clinical trial with SDC-1801 submitted to the UK Medicines and Healthcare Products Regulatory Agency Sareum has made significant progress ...
Cambridge, UK, 8 November 2022 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces that the UK Medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback